Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB-Plus dose-escalation and expansion study in chronic refractory wounds
2025-522647-17-00Phase 2Authorised
- Sponsor
- HMG Biologics
- Start
- Apr 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of FB Plus in Chronic wound (3 arms), sponsored by HMG Biologics. Primary endpoints: Incidence and characterization of treatment-emergent adverse events, Changes in safety assessments and 10 more. Planned start Apr 2026; status: authorised.
02
Drugs
FB Plus
03
Conditions
Chronic wound
Beyond the preview
Go deeper on 2025-522647-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522647-17-00.